Aspiration–sclerotherapy Results in Effective Control of Liver Volume in Patients with Liver Cysts by van Keimpema, Loes et al.
ORIGINAL PAPER
Aspiration–sclerotherapy Results in Effective Control of Liver
Volume in Patients with Liver Cysts
Loes van Keimpema Æ Daan B. de Koning Æ
Simon P. Strijk Æ Joost P. H. Drenth
Received: 24 September 2007/Accepted: 5 November 2007/Published online: 26 February 2008
 The Author(s) 2008
Abstract Purpose To study the extent to which aspira-
tion–sclerotherapy reduces liver volume and whether this
therapy results in relief of symptoms. Results Four patients,
group I, with isolated large liver cysts, and 11 patients,
group II, with polycystic livers, underwent aspiration–
sclerotherapy. Average volume of aspirated cyst ﬂuid was
1,044 ml (range 225–2,000 ml) in group I and 1,326 ml
(range 40–4,200 ml) in group II. Mean liver volume before
the procedure was 2,157 ml (range 1,706–2,841 ml) in
group I and 4,086 ml (range 1,553–7,085 ml) in group II.
This decreased after the procedure to 1,757 ml (range
1,479–2,187 ml) in group I. In group II there was a sta-
tistically signiﬁcant decrease to 3,347 ml (range 1,249–
6,930 ml, P = 0.008). Volume reduction was 17.1%
(range -34.7% to -4.1%) and 19.2% (range -53.9% to
+2.4%) in groups I and II, respectively. Clinical severity of
all symptoms decreased, except for involuntary weight loss
and pain in group II. Conclusion Aspiration–sclerotherapy
is an effective means of achieving liver volume reduction
and relief of symptoms.
Keywords Liver cyst  PCLD  Aspiration  Ethanol 
Volumetry
Introduction
Isolated liver cysts are very frequent—they have been
detected in up to 18% of patients subjected to ultrasonog-
raphy or CT scan [1–3]. Liver cysts have been recognized
increasingly as the routine use of imaging studies has
become more widespread. The phenotype of a number of
inherited syndromes dictates the presence of hepatic cysts.
Radiographically, hepatic cysts in polycystic livers share
the same architecture and are thought to arise from aberrant
bile ducts [4].
Polycysticliverdisease(PCLD)isanautosomalinherited
condition characterized by the presence of numerous cysts
scattered throughout the liver. There are no, or only a few,
cysts in the kidneys, which distinguishes it from autosomal
dominant polycystic kidney disease (ADPKD), the most
common cause of polycystic liver disease [4]. Although the
hepatic phenotype of both syndromes is similar, the syn-
dromes are separate entities, as is illustrated by the fact that
both have different causative genes. PCLD is caused by
mutations in the PRKCSH gene and the SEC63 gene [5, 6]
whereas ADPKD is caused by mutations in the PKD-1 and
the PKD-2 genes [7]. PCLD probably results from ductal
plate malformation, which is characterized by a disturbance
in the physiological remodeling of the ductal plate [8].
The multiple cysts arise from progressive dilatation of the
abnormal ducts in biliary hamartomas [4], which are the
result of ductal plate malformation at the level of the small
intrahepatic bile ducts. These small bile ducts have lost
continuity with the remaining biliary tree, which explains
the non-communicating nature of the cysts in PCLD [9].
Hepaticcystsarerarelysymptomatic.Symptomscanarise
due to growth of the cysts and are usually due to abdominal
mass; examples include abdominal pain, early satiety,
dyspnea,nausea,andvomitingandaremostlyseeninfemales
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hypertension, cyst infection, and cyst rupture occur [10].
The majority of patients with multiple liver cysts are not
in need of therapy. When patients become symptomatic,
therapeutic options should be explored. The aim of therapy
is to reduce cyst volume in order to achieve relief of
symptoms and to prevent recurrence. Current management
consists of aspiration–sclerotherapy of selected cysts or
surgical approaches aimed at excising or obliterating cysts
[11]. Choice of treatment of PCLD is based on the number,
size, and location of the cysts and on local expertise.
Aspiration–sclerotherapy is a minor invasive option with
low morbidity. The technique was ﬁrst described in 1985
[12] after the realization that aspiration alone led to 100%
recurrence of cysts [13]. Improvement of this procedure
consists in additional sclerotherapy with ethanol or other
irritants (antibiotics), after aspiration of the cyst contents,
aimed at destroying the cyst lining epithelium [12, 14–16].
Though this method has slowly gained popularity, it is
unknownifandtowhatextentitreduceslivervolume,asthis
is arguably the main reason for the development of symp-
toms. Furthermore, it is unknown whether this treatment
actually beneﬁts patients in terms of relief of symptoms.
To this end we designed this study with two aims in
mind. First we aimed to evaluate the efﬁcacy of aspiration–
sclerotherapy in reduction of liver volume. Second we
wanted to know whether symptoms experienced by patients
with polycystic liver disease or large isolated hepatic cysts
were improved by the procedure.
Material and Methods
Subjects
Between October 2004 and May 2007, 15 symptomatic
patients underwent ultrasonographically guided aspiration–
sclerotherapy. Patients were subdivided into two groups.
Group I included four patients with isolated large liver cysts
(twomale, twofemale, meanage51.3 years(SD27.6,range
24–76 years)). Group II included 11 patients with PCLD,
deﬁned as[15 liver cysts (all female, mean age 55.0 years
(SD 12.7, range 35–81 years)). Four patients of group II,
carried a PRKCSH gene mutation and none of them had a
SEC63 gene mutation. The study was approved by the local
medical ethical review committee (CMO regio Arnhem
Nijmegen). All participants provided informed consent.
Procedure
All aspiration–sclerotherapy procedures to treat liver cysts
were performed on an out-patient basis. Patients were put
in a supine position. After locating a strategically located
symptomatic cyst, the overlying skin was locally anaes-
thetized with lidocaine and a small incision was made. We
performed ultrasound guided aspiration of the cyst with a 5
French straight catheter needle system or a 7 French pigtail
needle system. The cyst was emptied via a three-way
stopcock without allowing air to enter the collapsed cyst.
After emptying the cyst, we proceeded to instill 96% eth-
anol (to a maximum of 27% of total aspirated volume). We
usually inject and evacuate ethanol several times in order
to ensure maximal ablation of the cystic wall. After 15 min
(range 10–20 min) the procedure was terminated by
evacuation of all remaining ethanol and removal of the
catheter. If a patient experienced pain or complete aspira-
tion of cyst ﬂuid was not possible, in most instances
because of the presence of cystic blood clots, no ethanol
was instilled into the cyst and the session was abandoned.
Volumetry
Each patient undergoing aspiration–sclerotherapy was
subjected to two multidetector computed tomography (CT)
scans, before and after treatment, with a maximum interval
of 18 months between the scans. Liver volumetry was
performed on the multidetector CT-scan (Siemens Som-
atom Sensation 64) before the ﬁrst session and, if there
were more sessions, after the last session.
The digital CT images with 3 mm slice thickness were
used for digital volumetry, using the Siemens Volume
application. The liver was outlined manually, marking each
1–5 cm with a mouse click until the entire liver perimeter
was outlined. This step was repeated each 9 mm through
the complete length of the liver. The software intrapolated
the intermediate slices and calculated the areas within the
indicated circumference. Finally, the software calculated
the liver volume by use of the equation V = S 9 A, where
S is the interval of the serial slices (mm) and A is the
enclosed area (cm
2). For comparison, four normal livers
were evaluated. We measured four livers from four sub-
jects that had had a CT scan for liver-unrelated reasons.
There the average normal liver volume was 1,550 ml
(range 1,230–1,751 ml). The average difference between
intraindividual observations was 35 ml (range 2–85 ml),
measured in seven livers. That between interindividual
observations was 52 ml (range 38–72 ml), measured in
four livers.
Questionnaire
Patients were asked to complete a questionnaire with 12
abdomen-symptom-speciﬁc items. This symptom-based
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after treatment [17]. It is a self-completed questionnaire,
that has been validated, and can be used in a variety of
clinical settings. This questionnaire included questions
about the severity of the symptoms during the previous
4 weeks rated on a seven-point Likert scale (with 0
meaning ‘‘absent’’ and 6 ‘‘very severe’’). A score of two or
more was regarded as symptom presence. Furthermore,
demographic variables, duration of symptoms, and overall
severity (on a 100 mm visual analogue scale) were recor-
ded. Questions that were not completed properly were
excluded from further analysis.
Statistical Analysis
Paired t-tests were performed to study differences between
liver volume before and after the procedure and the
severity of symptoms. Pearson’s correlation coefﬁcient was
used to compare the amount of aspirated ﬂuid and liver
volume reduction. A difference with a P-value of \0.05
was considered statistically signiﬁcant.
Results
Patients
Patient characteristics are shown in Table 1. No session
was terminated prematurely because of pain.
In total there were six aspiration–sclerotherapy sessions
in group I and 23 in group II. A total of 30 cysts were
aspirated in group II. Two patients in group I and ﬁve in
group II were subjected to a single session, while the
remaining two and six had from two to four sessions. In
group II, we aspirated a maximum of two cysts during each
session. Figure 1 shows a typical result of the aspiration–
sclerotherapy (patient 3). Here, the procedure led to a
decrease in volume of 11.6%.
The average volume of aspirated cyst ﬂuid was 1,044 ml
(SD 729, range 225–2,000 ml) in group I and 1,326 ml (SD
1194, range 40–4,200 ml) in group II. The average amount
of ethanol instilled in the cysts was 5.7% of aspirated
volume (range 1.6–13.3%) in group I and 8.3% (range 0.7–
27%) in group II but never more than 50 ml.
Mean clinical follow-up period after the last session was
21 months (range 8–30 months) for group I and
14.5 months (range 3–27 months) for group II. Four
patients, one of group I and three of group II, were referred
for laparoscopic fenestration because of failure of symp-
toms to improve.
Volumetry
Average liver volume before the procedure, 2,157 ml
(range 1,706–2,841 ml) in group I and 4,086 ml (range
1,553–7,085 ml) in group II, was (statistically) much
higher than that of control livers, because of the large
volumes of cystic livers. Average liver volume decreased
Table 1 Patient characteristics
a Age reﬂects current age
b Indicates a PRKCSH-
mutation
Sex Age
a Diagnosis Number of
sessions
Total aspirated
cyst ﬂuid (ml)
CT-volume
before (ml)
CT-volume
after (ml)
Liver volume
change (%)
Group I
1 F 24 Single cysts 2 950 1,801 1,479 -17.9
2 M 31 Single cysts 2 1,000 2,281 2,187 -4.1
3 M 74 Single cysts 1 225 1,706 1,508 -11.6
4 F 76 Single cysts 1 2,000 2,841 1,855 -34.7
Group II
5
b F 40 PCLD 4 1,310 5,489 4,974 -9.4
6
b F 58 PCLD 4 505 4,897 4,145 -15.4
7 F 65 PCLD 1 40 1,553 1,441 -7.2
8 F 81 PCLD 1 1,400 3,004 2,424 -19.3
9
b F 55 PCLD 1 1,300 4,195 2,877 -31.4
10
b F 35 PCLD 3 980 4,275 4,376 +2.4
11 F 61 PCLD 2 1,100 2,809 2,164 -23.0
12 F 45 PCLD 1 500 6,959 6,930 -0.4
13 F 60 PCLD 2 4,200 7,085 4,637 -34.6
14 F 57 PCLD 1 200 1,974 1,603 -18.8
15 F 48 PCLD 3 3,050 2,707 1,249 -53.9
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123to 1,757 ml (range 1,479–2,187 ml) in group I and
3,347 ml (range 1,249–6,930 ml) in group II after the
procedures. This represents a reduction of volume of 17.1%
(range -34.7% to -4.1%) in group I and 19.2% (range
-53.9% to +2.4%) in group II. Liver volume reduction
reached statistical signiﬁcance in group II with a mean liver
volume decrease of 739 ml (95%CI 236–1,241 ml,
P = 0.008). Liver volume decreased in all patients of
group I and in nine patients in group II. One patient had
only a slight decrease of liver volume and one patient had a
slight increase.
There was an excellent, signiﬁcant, correlation between
the volume removed by cyst aspiration and the ﬁnal liver
volume as assessed on follow-up CT scanning. In essence,
larger volume on aspiration led to better results in terms of
liver volume reduction (r =- 0.87 P\0.0001) (Fig. 2).
Questionnaire
The response to the questionnaire was 100%. Table 2 shows
the average degree of symptoms during treatment. There
were two patients, both of group II, which did not experi-
ence any pain during treatment. Nausea and vomiting was
noted by three patients, two of group I and one of group II.
Table 3 displays the average degree of symptoms before
andaftertreatment.Inbothgroups,theclinicalseverityofall
symptomsdecreased, exceptforinvoluntary weight loss and
pain in group II. Speciﬁcally, the severity of postprandial
fullness and abdominal distension decreased more than that
of the other symptoms. Most patients of both groups expe-
rienced a decrease of all listed symptoms, although some
patients had an increase of one of the symptoms after
treatment. Total pain increased in four patients (all in group
II), was stable in three (one in group I and two in group II),
while the remaining patients had a decrease in total pain.
Fig. 1 (a) CT scan of the liver of a 74-year-old man with ADPKD and a large isolated cyst. (b) CT scan of the same region of the liver 4 months
later shows a regression of the isolated cyst. (c) Ultrasound of the same cyst before aspiration. (d) Ultrasound-guided aspiration of the cyst
Fig. 2 Relationship between total aspirated cyst ﬂuid and the liver
volume (r =- 0.86, P\0.0001)
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123None of the differences reached the level of statistical
signiﬁcance.
Discussion
We found that aspiration–sclerotherapy in patients with
liver cysts leads to a substantial reduction of liver volume
and a corresponding decline of symptoms. It is minimally
invasive and safe, can be done on an out-patient basis, and
complications are rare. The therapy is effective for single
liver cysts and for polycystic livers with large cysts,
because it reduces liver volume and probably relieves
symptoms. This will make aspiration–sclerotherapy part of
the armamentarium to treat PCLD and large solitary liver
cysts.
We evaluated four livers with a single cyst and 11
polycystic livers. The procedure as described in this study
resulted in an average liver volume reduction of 17.1% and
19.2%, respectively. We elected not to treat patients with
small liver cysts as it is unlikely this would result in sub-
stantial reduction of liver volume.
An interesting difference between the two groups is the
total liver volume. The volumes of livers with a single cyst,
are smaller than polycystic livers. We found that the efﬁ-
cacy of the aspiration–sclerotherapy in terms of liver
volume reduction was similar in both groups.
We evaluated total liver volume rather than individual
cysts, because symptoms in, especially, patients with
polycystic livers arise from compression by severe hepa-
tomegaly rather than the volume effect of a single
strategically located cyst. As such, our study stands out
because previously studies recorded the size of individual
cysts rather than total liver volume. Liver volume mea-
surement is used for the work-up for liver transplant. In
our hands the measurement was reproducible, and had
limited intra and interoperator variability. Although the
procedure is currently not used in clinical practice it
provides highly useful information and in the near future
might be used to tailor the treatment options for PCLD
[18–20].
The efﬁcacy of the aspiration–sclerotherapy exceeded
our expectation and could be achieved in all except a single
patient of group II. The liver volume of this patient
increased with by 2%, despite an aspirated volume of
980 ml. At the moment it is uncertain why this single cyst
was refractory to treatment. She was among two other
patients of group II and one of group I who were referred
for subsequent laparoscopic cyst fenestration.
We learned from our study that it is far more effective to
evacuate large liver cysts (arbitrarily deﬁned as[8 cm) as
these lead to a signiﬁcantly better volume reduction
(Fig. 2). On the other hand, repeated (2–3) aspirations of
these cysts are necessary to yield an acceptable volume
reduction. In our hands the procedure does not lead to
complete obliteration of the cyst but rather prevents it from
expanding. For example, we were able to decrease large
liver cysts ([20 cm) to less than 5 cm with adequate
symptom control.
We used a questionnaire to score the severity of symp-
toms. Overall, there was an average decrease in the severity
of symptoms. Abdominal distension and postprandial
fullness were among the symptoms that were scored, in
both groups, as most severe before treatment. These
symptoms decreased after treatment. Moreover, most
patients experience pain relief.
Table 2 The average severity of symptoms during treatment
Symptom
a Group I Group II
1. Pain
Insertion of catheter 2.7 2.0
During aspiration 2.8 1.5
During ethanol instillation 1.8 2.2
2. Nausea 0.9 0.5
3. Vomiting 0.7 0.3
a Symptoms were scored on a range of 0–6 (0 = no symptom;
6 = very severe)
Table 3 Average severity of symptoms before and after treatment
Symptom
a Group I Group II
Before After Before After
1. Abdominal pain
General 1.7 1.0 0.9 0.6
Postprandial 1.7 0.7 1.0 0.4
Fasting 1.3 0.7 0.6 0.3
Unrelated to defecation 0.7 0 0.8 0.3
2. Epigastric pain
General 1.2 0.3 1.7 1.5
During daytime 0.8 0.2 1.5 1.5
At night/asleep 1.0 0.3 1.4 1.4
3. Heartburn 0 0 1.6 1.0
4. Regurgitation 0 0 1.6 1.2
5. Nausea 0.7 0.3 1.1 1.0
6. Vomiting 0.7 0.3 0.2 0.2
7. Loss of appetite 1.2 0.5 1.5 1.2
8. Postprandial fullness 1.3 0.8 3.0 2.1
9. Shortness of breath 0.7 0.2 1.0 0.7
10. Abdominal distension 2.0 0.7 3.2 1.7
11. Involuntary weight loss 0.3 0 0.3 0.7
12. Pain 2.1 1.3 1.4 1.6
a Symptoms were scored on a range of 0–6 (0 = no symptom,
6 = very severe)
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123Apart from pain, we observed no complications such as
infection of liver cysts or pleural ﬂuid effusion [16]. Pain
could occur at any time during the procedure—when the
catheter passes the liver capsule, upon ﬂuid aspiration, and,
ﬁnally, after injection of ethanol in the cyst. Patients
describe the pain during ethanol instillation as a burning,
but in most instances that abates quickly. Pain is seen in all
studies as most common drawback of aspiration [12, 14,
16, 21–26].
Aspiration–sclerotherapy has several advantages over
other approaches, because it is easy, can be performed on
an out-patient basis and leads to few complications [14,
27]. Our procedure has similarities to, and differences
from, sclerotherapy described elsewhere [12, 14, 16, 21–
26, 28]. Similar to many other studies we used ethanol as
sclerosing agent. It destroys the lining epithelium and leads
to ﬁbrotic obliteration which will impede production of
cyst ﬂuid [12]. Other sclerosing agents such as minocy-
cline, tetracycline, or doxycycline destroy the lining
epithelium by virtue of the highly acidic pH [14, 15]. These
agents appeared to be similarly effective to ethanol [16]. A
risk of the use of a sclerosing agent such as ethanol is
marked sclerosis of the bile ducts when it is injected into a
cyst that communicates with the biliary tree [12]. Therefore
some authors argue that ﬂuoroscopy should be used prior to
instillation of ethanol [12, 16, 22, 23, 25, 28, 29]. We
treated superﬁcially located cysts that are not likely to
communicate with the biliary tree, hence avoiding the need
for veriﬁcation by ﬂuoroscopy. There is lack of objective
data concerning optimum exposure time. Some authors
instill ethanol for prolonged period but we chose a limited
exposure time in order to limit the chances for complica-
tions [12, 14, 16, 22–26]. This is supported by another
study that elected to leave a catheter for drainage after the
sclerotherapy. The sclerotherapy was repeated if more than
10–15 ml cyst ﬂuid was produced. In contrast with our
ﬁndings, this study reports complications such as infection
and pleural ﬂuid effusion [16]. Most likely, these compli-
cations could have been avoided if the catheter was
removed immediately after sclerotherapy. Several studies
reported that the patients need to be turned over to various
positions, in order to permit ethanol to come into contact
with all surfaces of the cyst cavity [12, 14, 15, 22, 23, 25,
26, 28]. This procedure was not part of our applied
technique.
Aspiration–sclerotherapy is indicated in patients with
symptoms that are associated with large liver cysts
([5 cm) and/or dominant cysts.
Other patients, especially those with multiple small
cysts scattered throughout the liver parenchyma, are can-
didates for other therapeutic options—open or laparoscopic
liver cyst fenestration, partial liver resection, or liver
transplantation.
The choice between these modalities is made on the
basis of the location of cysts, volume of the liver, and
surgical experience. Open fenestration of cysts is more
effective in terms of volume reduction, but the morbidity of
laparoscopic fenestration is lower than that of the open
procedure [30]. Patients with livers with a dominantly
affected liver segment might be candidates for a partial
liver resection, but the morbidity rate is higher than for the
other procedures. Finally, liver transplantation is indicated
if other therapies are no option or failed and if the patient is
severely incapacitated by the large volume of the liver [10].
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